Sensory symptoms in Parkinson's disease;Síntomas sensoriales en la enfermedad de Parkinson

Revista de Neurologia

Volumn 50, Issue SUPPL. 2, 2010, Pages

  Santos García, Diego ^a   Aneiros Díaz, Ángel ^a   Macías Arribi, Mercedes ^a   Llaneza González, Miguel A ^a   Abella Corral, Javier ^a   Santos Canelles, Helena ^a  

^a Universidad de La Coruña   (Spain)

Author keywords

Hypoacusia; Hyposmia; Non motor symptoms; Pain; Parkinson's disease; Sensory symptoms

Indexed keywords

ACETYLSALICYLIC ACID; BOTULINUM TOXIN; DIPYRONE; GABAPENTIN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PREGABALIN; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CLASSIFICATION; HEARING LOSS; HUMAN; HYPOSMIA; MYALGIA; PAIN; PARKINSON DISEASE; PREDICTOR VARIABLE; SENSORY DYSFUNCTION; SMELLING DISORDER; TASTE DISORDER; VISUAL DISORDER;

DIAGNOSIS, DIFFERENTIAL; HUMANS; PAIN; PARKINSON DISEASE; SENSATION DISORDERS;

EID: 77949531524     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Poewe W. Non-motor symptoms in Parkinson's disease. Eur J Neurol 2008; 15 (Suppl 1): S14-20.
2. Parkinson J. An essay on the shaking palsy. London: Sherwood, Neely & Jones; 1817.
3. Charcot JM. Lectures on diseases on the nervous system. London: The New Syndenham Society; 1877.
4. Snider SR, Fahn S, Isgreen WP, Cote LJ. Primary sensory symptoms in parkinsonism. Neurology 1976; 26: 423-9.
5. Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002; 59: 408-13.
6. Goetz CG, Tanner CM, Levy M, Wilson RS, Garron DC. Pain in Parkinson's disease. Mov Disord 1986; 1: 45-9.
7. Lee MA, Walker RW, Hildreth TJ, Prentice WN. A survey of pain in idiopathic Parkinson's disease. J Pain Symptom Manage 2006; 32: 462-9.
8. Beiske AG, Loge JH, Rønningen A, Svensson E. Pain in Parkinson's disease: prevalence and characteristics. Pain 2009; 141: 173-7.
9. Quittenbaum BH, Grahn B. Quality of life and pain in Parkinson's disease: a controlled cross-sectional study. Parkinsonism Relat Disord 2004; 10: 129-36.
10. Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006; 5: 235-45.
11. Loge JH, Kaasa S. Short Form-36 (SF-36) healthy survey: normative data from the general Norwegian population. Scand J Soc Med 1998; 26: 250-9.
12. Vela L. El dolor en la enfermedad de Parkinson. Revista Española de Trastornos del Movimiento 2006; 2: 11-6.
13. Ford B. Pain in Parkinson's disease. Clin Neurosci 1998; 5: 63-72.
14. Koller WC. Sensory symptoms in Parkinson's disease. Neurology 1984; 34: 957-9.
15. Osterberg A, Boivie J, Thuomas KA. Central pain in multiple sclerosis prevalence and clinical characteristics. Eur J Pain 2005; 9: 531-42.
16. Widar M, Samuelsson L, Karlsson-Tivenius S, Ahlstrøm G. Long-term pain conditions after stroke. J Rehabil Med 2002; 34: 165-70.
17. Djaldetti R, Shifrin A, Rogowski Z, Sprecher E, Melamed E, Yarnitsky D. Quantitative measurement of pain sensation in patients with Parkinson disease. Neurology 2004; 62: 2171-5.
18. Scherder E, Wolters E, Polman C, Sergeant J, Swaab D. Pain in Parkinson's disease and multiple sclerosis: its relation to the medial and lateral pain systems. Neurosci Biobehav Rev 2005; 29: 1047-56.
19. Brefel-Courbon C, Payoux P, Thalamas C, Ory F, Quelven I, Chollet F, et al. Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord 2005; 20: 1557-63.
20. Pacchetti C, Albani G, Martignoni E, Godi L, Alfonsi E, Nappi G. 'Off' painful dystonia in Parkinson's disease treated with botulinum toxin. Mov Disord 1995; 10: 333-6.
21. Serratrice G, Michel B. Pain in Parkinson's disease patients. Rev Rheum Engl Ed 1999; 66: 331-8.
22. Quinn NP, Koller WC, Lang AE, Marsden CD. Painful Parkinson's disease. Lancet 1986; 1: 1366-9.
23. Ford B, Louis ED, Greene P, Fahn S. Oral and genital pain syndromes in Parkinson's disease. Mov Disord 1996; 11: 421-6.
24. Sandyk R. Anticholinergic-induced analgesia: possible role for the cholinergic system in abnormal sensory symptoms in Parkinson's disease. Postgrad Med J 1986; 62: 749-51.
25. Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, et al. Pharmacological management of chronic neuropathic pain -Consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007; 12: 13-21.
26. Honey CR, Stoessl AJ, Tsui JK, Schulzer M, Calne DB. Unilateral pallidotomy for reduction of parkinsonian pain. J Neurosurg 1999; 91: 198-201.
27. Loher TJ, Burgunder JM, Weber S, Sommerhalder R, Krauss JK. Effect of chronic pallidal deep brain stimulation on off period dystonia and sensory symptoms in advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 2002; 73: 395-9.
28. Doty RL, Golbe LI, Mckeown DA, Stern MB, Lerach CM, Crawford D. Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson's disease. Neurology 1993; 43: 962-5.
29. Stern MB, Doty RL, Dotti M, Corcoran P, Crawford D, McKeown DA, et al. Olfactory function in Parkinson's disease. Neurology 1994; 44: 266-8.
30. Doty RL. Olfaction in Parkinson's disease. Parkinsonism Relat Disord 2007; 13 (Suppl 3): S225-8.
31. Wenning GK, Shephard B, Hawkes C, Petruckevitch A, Lees A, Quinn N. Olfactory function in atypical parkinsonian syndromes. Acta Neurol Scand 1995; 91: 247-50.
32. Katzenschlager R, Zijlmans J, Evans A, Watt H, Lees AJ. Olfactory function distinguishes vascular parkinsonism from Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75: 1749-52.
33. Hawkes C. Olfaction in neurodegenerative disorder. Adv Otorhinolaryngol 2006; 63: 133-51.
34. Pearce RK, Hawkes CH, Daniel SE. The anterior olfactory nucleus in Parkinson's disease. Mov Disord 1995; 10: 283-7.
35. Huisman E, Uylings HB, Hoogland PV. A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson's disease. Mov Disord 2004; 19: 687-92.
36. Braak H, Del Tredici K, Rüb U, De Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
37. Khan NL, Katzenschlager R, Watt H, Bhatia KP, Wood NW, Quinn N, et al. Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease. Neurology 2004; 62: 1224-6.
38. Ansari KA, Johnson A. Olfactory function in patients with Parkinson's disease. J Chronic Dis 1975; 28: 493-7.
39. Mesholam RI, Moberg PJ, Mahr RN, Doty RL. Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer's and Parkinson's diseases. Arch Neurol 1998; 55: 84-90.
40. Tissingh G, Berendse HW, Bergmans P, DeWaard R, Drukarch B, Stoof JC, et al. Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosis. Mov Disord 2001; 16: 41-6.
41. Hawkes CH. Olfaction in neurodegenerative disorders. Mov Disord 2003; 18: 364-72.
42. Wilson RS, Arnold SE, Buchman AS, Tang Y, Bennett DA. Odor identification and progression of parkinsonian signs in older persons. Exp Aging Res 2008; 34: 173-87.
43. Ponsen MM, Stoffers D, Booij J, Van Eck-Smit BL, Wolters EC, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004; 56: 173-81.
44. Siderowf A, Stern MB. Premotor Parkinson's disease: clinical features, detection, and prospects for treatment. Ann Neurol 2008; 64 (Suppl 2): S139-47.
45. Sommer U, Hummel T, Cormann K, Mueller A, Frasnelli J, Kropp J, et al. Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 2004; 19: 1196-202.
46. Parkkinen L, Silveira-Moriyama L, Holton JL, Lees AJ, Revesz T. Can olfactory bulb biopsy be justified for the diagnosis of Parkinson's disease? Comments on 'Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders'. Acta Neuropathol 2009; 117: 213-4 [author reply 217-8].
47. Beach TG, White CL III, Hladik CL, Sabbagh MN, Connor DJ, Shill HA, et al. Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol 2009; 117: 169-74.
48. Double KL, Rowe DB, Hayes M, Chan DK, Blackie J, Corbett A, et al. Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test. Arch Neurol 2003; 60: 545-9.
49. Antunes MB, Bowler R, Doty RL. San Francisco/Oakland Bay Bridge Welder Study: olfactory function. Neurology 2007; 69: 1278-84.
50. Krantz EM, Schubert CR, Dalton DS, Zhong W, Huang GH, Klein BE, et al. Test-retest reliability of the San Diego Odor Identification Test and comparison with the Brief Smell Identification Test. Chem Senses 2009; 34: 435-40.
51. Henkin RI, Velicu I, Schmidt L. An open-label controlled trial of theophylline for treatment of patients with hyposmia. Am J Med Sci 2009; 337: 396-406.
52. Levy LM, Henkin RI, Lin CS, Hutter A, Schellinger D. Increased brain activation in response to odors in patients with hyposmia after theophylline treatment demonstrated by fMRI. J Comput Assist Tomogr 1998; 22: 760-70.
53. Armstrong RA. Visual signs and symptoms of Parkinson's disease. Clin Exp Optom 2008; 91: 129-38.
54. Azulay JP, Mesure S, Amblard B, Pouget J. Increased visual dependence in Parkinson's disease. Percept Mot Skills 2002; 95: 1106-14.
55. Jones RD, Donaldson IM. Fractionation of visuo-perceptual dysfunction in Parkinson's disease. J Neurol Sci 1995; 131: 43-50.
56. Jones RD, Donaldson IM, Timmings PL. Impairment of high-contrast visual activity in Parkinson's disease. Mov Disord 1992; 7: 232-8.
57. Rodnitzky RL. Visual dysfunction in Parkinson's disease. Clin Neurosci 1998; 5: 102-6.
58. Veselá O, Rizicka E, Jech R, Roth J, Stepánková K, Mecír P, et al. Colour discrimination impairment is not a reliable early marker of Parkinson's disease. J Neurol 2001; 248: 975-8.
59. Büttner T, Kuhn W, Patzold T, Przuntek H. L-dopa improves colour vision in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1994; 7: 13-9.
60. Yenice O, Onal S, Midi I, Ozcan E, Temel A, I-Gunal D. Visual field analysis in patients with Parkinson's disease. Parkinsonism Relat Disord 2008; 14: 193-8.
61. Biousse V, Newman NJ, Carroll C, Mewes K, Vitek JL, Bakay RA, et al. Visual fields in patients with posterior GPi pallidotomy. Neurology 1998; 50: 258-65.
62. Shibasaki H, Tsuji S, Kuroiwa Y. Oculomotor abnormalities in Parkinson's disease. Arch Neurol 1979; 36: 360-4.
63. Biousse V, Skibell BC, Watts RL, Loupe DN, Drews-Botsch C, Newman NJ. Ophthalmologic features of Parkinson's disease. Neurology 2004; 62: 177-80.
64. Armstrong RA, Syed AB. Alzheimer's disease and the eye. Ophthalmic Physiol Opt 1996; 16 (Suppl 1): S2-8.
65. Ondo WG, Sutton L, Dat Vuong K, Lai D, Jankovic J. Hearing impairment in essential tremor. Neurology 2003; 61: 1093-7.
66. Lewald J, Schirm SN, Schwarz M. Sound lateralization in Parkinson's disease. Brain Res Cogn Brain Res 2004; 21: 335-41.
67. Shin HW, Kang SY, Sohn YH. Dopaminergic influence on disturbed spatial discrimination in Parkinson's disease. Mov Disord 2005; 20: 1640-43.
68. Sathian K, Zangaladze A, Green J, Vitek JL, DeLong MR. Tactile spatial acuity and roughness discrimination: impairments due to aging and Parkinson's disease. Neurology 1997; 49: 168-77.
69. Shah M, Deeb J, Fernando M, Noyce A, Visentin E, Findley LJ, et al. Abnormality of taste and smell in Parkinson's disease. Parkinsonism Relat Disord 2009; 15: 232-7.